IMNM241220P7500
- 0.05
- 0.000.00%
Immunome Newsroom
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
Immunome President Acquires 24% More Stock
Immunome Insider Bought Shares Worth $962,181, According to a Recent SEC Filing
Insider Purchase: President and CEO of $IMNM (IMNM) Buys 66,057 Shares
Immunome CEO Clay Siegall Acquires $962,181 in Company Stock
Express News | Immunome Inc Files for Resale of up to 1.8 Mln Shares by the Selling Stockholder - SEC Filing
Immunome (IMNM) Receives a Buy From J.P. Morgan
Express News | Immunome Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results
Wedbush Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33
Immunome Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Immunome(IMNM.US) With Buy Rating, Cuts Target Price to $21
Immunome Analyst Ratings
Immunome Price Target Lowered to $21 From $23 at Piper Sandler
Express News | Immunome Inc : Piper Sandler Cuts Target Price to $21 From $23
TD Cowen Maintains Immunome(IMNM.US) With Buy Rating
Promising Growth Potential for Immunome: Buy Rating Backed by Strategic Acquisitions and Innovative Pipeline
Immunome, Inc GAAP EPS of -$0.78 Misses by $0.21
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates